Journal
MOVEMENT DISORDERS
Volume 32, Issue 1, Pages 108-114Publisher
WILEY
DOI: 10.1002/mds.26813
Keywords
Progressive supranuclear palsy; tau; positron emission tomography; basal ganglia
Categories
Funding
- European Research Council
- Swedish Research Council
- Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
- Crafoord Foundation
- Swedish Brain Foundation
- Skane University Hospital Foundation
- Swedish Alzheimer Association
- Stiftelsen for Gamla Tjanarinnor
- Swedish federal government
Ask authors/readers for more resources
Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP. Methods: Regional tau accumulation was studied using F-18-AV-1451 PET in 11 patients with PSP and 11 agematched healthy controls in the Swedish BioFinder study. Results: F-18-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r=.43-. 78, P <. 05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r=.74, P <. 05). However, no F-18-AV- 1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates. Conclusion: We found higher F-18-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, F-18-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether F-18-AV-1451 PET might be useful as a progression marker in clinical PSP trials. (C) The Authors. Movement Disorders published byWiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available